• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性冠脉综合征患者中GRACE风险评分与冠状动脉脂质核心斑块的关系

Relation of GRACE Risk Score to Coronary Lipid Core Plaques in Patients with Acute Coronary Syndrome.

作者信息

Sato Takanori, Saito Yuichi, Kitahara Hideki, Kobayashi Yoshio

机构信息

Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine, Chiba 260-8670, Japan.

出版信息

Life (Basel). 2023 Feb 24;13(3):630. doi: 10.3390/life13030630.

DOI:10.3390/life13030630
PMID:36983786
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10054497/
Abstract

The GRACE risk score is established to predict thrombotic events in patients with acute coronary syndrome (ACS). Although thrombotic events including myocardial infarction after ACS are mainly attributable to vulnerable plaque formation, whether the GRACE score correlates with coronary lipid-rich plaque is unclear. A total of 54 patients with ACS undergoing primary percutaneous coronary intervention under near-infrared spectroscopy intravascular ultrasound (NIRS-IVUS) guidance were included in a prospective manner. Patients were divided into two groups according to the median of the GRACE risk score. Coronary lipid plaques in the target vessel were assessed by NIRS-IVUS with lipid core burden index (LCBI) and a maximum LCBI in 4 mm (maxLCBI). The receiver operating characteristics (ROC) curve analysis was performed based on the major adverse cardiovascular events as an exploratory analysis. The GRACE risk score was significantly and positively correlated with LCBI ( = 0.31, = 0.03) and maxLCBI ( = 0.38, = 0.006). LCBI (111.7 ± 85.7 vs. 169.0 ± 83.5, = 0.02) and maxLCBI (428.5 ± 227.1 vs. 600.6 ± 227.7, = 0.009) in the target vessel were significantly higher in the high GRACE risk score group than their counterpart. In the ROC curve analysis, LCBI and maxLCBI were predictive for clinical events. In conclusion, the higher GRACE risk score may serve as a discriminator of risk comprising more lipid-rich plaques as an underlying mechanism of an increased risk of thrombotic events after ACS. In patients with ACS, the higher GRACE risk score was significantly and modestly associated with greater coronary lipid plaques in the target vessel.

摘要

全球急性冠状动脉事件注册(GRACE)风险评分用于预测急性冠状动脉综合征(ACS)患者的血栓形成事件。尽管ACS后的血栓形成事件(包括心肌梗死)主要归因于易损斑块的形成,但GRACE评分与冠状动脉富含脂质斑块之间的相关性尚不清楚。本研究前瞻性纳入了54例在近红外光谱血管内超声(NIRS-IVUS)引导下接受直接经皮冠状动脉介入治疗的ACS患者。根据GRACE风险评分的中位数将患者分为两组。通过NIRS-IVUS采用脂质核心负荷指数(LCBI)和4毫米最大LCBI(maxLCBI)评估靶血管中的冠状动脉脂质斑块。基于主要不良心血管事件进行受试者操作特征(ROC)曲线分析作为探索性分析。GRACE风险评分与LCBI(r = 0.31,P = 0.03)和maxLCBI(r = 0.38,P = 0.006)显著正相关。高GRACE风险评分组靶血管中的LCBI(111.7±85.7 vs. 169.0±83.5,P = 0.02)和maxLCBI(428.5±227.1 vs. 600.6±227.7,P = 0.009)显著高于低GRACE风险评分组。在ROC曲线分析中,LCBI和maxLCBI可预测临床事件。总之,较高的GRACE风险评分可能作为一种风险判别指标,提示存在更多富含脂质的斑块,这是ACS后血栓形成事件风险增加的潜在机制。在ACS患者中,较高的GRACE风险评分与靶血管中更大的冠状动脉脂质斑块显著且适度相关。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/b23e27fff722/life-13-00630-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/f1d7e64b1590/life-13-00630-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/c4a1a4b3e915/life-13-00630-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/d680785ba997/life-13-00630-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/bc6a350c8c39/life-13-00630-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/bdb4d0013700/life-13-00630-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/b23e27fff722/life-13-00630-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/f1d7e64b1590/life-13-00630-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/c4a1a4b3e915/life-13-00630-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/d680785ba997/life-13-00630-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/bc6a350c8c39/life-13-00630-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/bdb4d0013700/life-13-00630-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e658/10054497/b23e27fff722/life-13-00630-g006.jpg

相似文献

1
Relation of GRACE Risk Score to Coronary Lipid Core Plaques in Patients with Acute Coronary Syndrome.急性冠脉综合征患者中GRACE风险评分与冠状动脉脂质核心斑块的关系
Life (Basel). 2023 Feb 24;13(3):630. doi: 10.3390/life13030630.
2
Coronary lipid-rich plaque characteristics in Japanese patients with acute coronary syndrome and stable angina: A near infrared spectroscopy and intravascular ultrasound study.日本急性冠状动脉综合征和稳定型心绞痛患者的冠状动脉富脂斑块特征:一项近红外光谱和血管内超声研究。
Int J Cardiol Heart Vasc. 2021 Mar 11;33:100747. doi: 10.1016/j.ijcha.2021.100747. eCollection 2021 Apr.
3
Intracoronary Near-Infrared Spectroscopy to Predict No-Reflow Phenomenon During Percutaneous Coronary Intervention in Acute Coronary Syndrome.冠状动脉内近红外光谱技术预测急性冠脉综合征经皮冠状动脉介入治疗中的无复流现象。
Am J Cardiol. 2024 May 15;219:17-24. doi: 10.1016/j.amjcard.2024.03.009. Epub 2024 Mar 13.
4
Intracoronary near-infrared spectroscopy and the risk of future cardiovascular events.冠状动脉内近红外光谱和未来心血管事件的风险。
Open Heart. 2019 Feb 9;6(1):e000917. doi: 10.1136/openhrt-2018-000917. eCollection 2019.
5
In vivo relationship between near-infrared spectroscopy-detected lipid-rich plaques and morphological plaque characteristics by optical coherence tomography and intravascular ultrasound: a multimodality intravascular imaging study.体内近红外光谱检测富含脂质斑块与光学相干断层扫描和血管内超声检测形态学斑块特征的关系:一项多模态血管内成像研究。
Eur Heart J Cardiovasc Imaging. 2021 Jun 22;22(7):824-834. doi: 10.1093/ehjci/jez318.
6
Near-infrared spectroscopy-derived lipid core burden index predicts adverse cardiovascular outcome in patients with coronary artery disease during long-term follow-up.近红外光谱衍生的脂质核心负荷指数可预测冠心病患者长期随访期间的不良心血管结局。
Eur Heart J. 2018 Jan 21;39(4):295-302. doi: 10.1093/eurheartj/ehx247.
7
Near-infrared spectroscopy for intracoronary detection of lipid-rich plaques to understand atherosclerotic plaque biology in man and guide clinical therapy.近红外光谱技术用于冠状动脉内脂质丰富斑块的检测,以了解人类动脉粥样硬化斑块的生物学特性,并指导临床治疗。
J Intern Med. 2015 Aug;278(2):110-25. doi: 10.1111/joim.12381. Epub 2015 Jun 19.
8
Relation of Plasma Xanthine Oxidoreductase Activity to Coronary Lipid Core Plaques Assessed by Near-Infrared Spectroscopy Intravascular Ultrasound in Patients With Stable Coronary Artery Disease.稳定型冠状动脉疾病患者应用近红外光谱血管内超声检测血浆黄嘌呤氧化酶活性与冠状动脉脂核斑块的关系。
Am J Cardiol. 2020 Apr 1;125(7):1006-1012. doi: 10.1016/j.amjcard.2019.12.043. Epub 2020 Jan 9.
9
Impact of clinical presentations on lipid core plaque assessed by near-infrared spectroscopy intravascular ultrasound.经近红外光谱血管内超声评估的临床特征对脂核斑块的影响。
Int J Cardiovasc Imaging. 2021 Apr;37(4):1151-1158. doi: 10.1007/s10554-020-02107-w. Epub 2020 Nov 17.
10
Identification of patients and plaques vulnerable to future coronary events with near-infrared spectroscopy intravascular ultrasound imaging: a prospective, cohort study.应用近红外光谱血管内超声成像技术识别易发生未来冠状动脉事件的患者和斑块:一项前瞻性队列研究。
Lancet. 2019 Nov 2;394(10209):1629-1637. doi: 10.1016/S0140-6736(19)31794-5. Epub 2019 Sep 27.

引用本文的文献

1
Cardiac computed tomography-derived coronary artery volume to myocardial mass for the prediction of risk stratification for acute coronary syndrome.心脏计算机断层扫描得出的冠状动脉容积与心肌质量之比用于预测急性冠状动脉综合征的风险分层。
Front Cardiovasc Med. 2025 Feb 13;12:1449148. doi: 10.3389/fcvm.2025.1449148. eCollection 2025.

本文引用的文献

1
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.依洛尤单抗对心肌梗死后他汀类药物治疗患者的冠状动脉斑块表型和负担的影响。
JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16.
2
Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial.依洛尤单抗联合高强度他汀治疗对急性心肌梗死患者冠状动脉粥样硬化的影响:PACMAN-AMI 随机临床试验。
JAMA. 2022 May 10;327(18):1771-1781. doi: 10.1001/jama.2022.5218.
3
Relation of glucose variability to vulnerable plaque formation in patients with coronary artery disease.
葡萄糖变异性与冠心病患者易损斑块形成的关系。
Heart Vessels. 2022 Sep;37(9):1516-1525. doi: 10.1007/s00380-022-02063-6. Epub 2022 Mar 30.
4
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives.经皮冠状动脉介入治疗后的抗血小板治疗:现状与未来展望。
Cardiovasc Interv Ther. 2022 Apr;37(2):255-263. doi: 10.1007/s12928-022-00847-1. Epub 2022 Mar 3.
5
Expert consensus statement for quantitative measurement and morphological assessment of optical coherence tomography: update 2022.光学相干断层扫描定量测量和形态评估专家共识声明:2022 年更新版。
Cardiovasc Interv Ther. 2022 Apr;37(2):248-254. doi: 10.1007/s12928-022-00845-3. Epub 2022 Feb 15.
6
Japanese Nationwide PCI (J-PCI) Registry Annual Report 2019: patient demographics and in-hospital outcomes.《2019年日本全国经皮冠状动脉介入治疗(J-PCI)注册报告:患者人口统计学特征及院内结局》
Cardiovasc Interv Ther. 2022 Apr;37(2):243-247. doi: 10.1007/s12928-021-00832-0. Epub 2022 Jan 12.
7
CVIT expert consensus document on primary percutaneous coronary intervention (PCI) for acute myocardial infarction (AMI) update 2022.CVIT 专家共识文件:急性心肌梗死(AMI)直接经皮冠状动脉介入治疗(PCI)更新 2022 版
Cardiovasc Interv Ther. 2022 Jan;37(1):1-34. doi: 10.1007/s12928-021-00829-9. Epub 2022 Jan 12.
8
Clinical expert consensus document on intravascular ultrasound from the Japanese Association of Cardiovascular Intervention and Therapeutics (2021).日本心血管介入治疗协会血管内超声临床专家共识文件(2021 年)。
Cardiovasc Interv Ther. 2022 Jan;37(1):40-51. doi: 10.1007/s12928-021-00824-0. Epub 2021 Nov 12.
9
Comparison of clinical outcomes between percutaneous coronary intervention for de novo lesions versus in-stent restenosis lesions.经皮冠状动脉介入治疗新发病变与支架内再狭窄病变的临床结局比较。
Cardiovasc Interv Ther. 2022 Apr;37(2):324-332. doi: 10.1007/s12928-021-00792-5. Epub 2021 Jul 5.
10
Association of GRACE Risk Score with Coronary Artery Disease Complexity in Patients with Acute Coronary Syndrome.GRACE风险评分与急性冠状动脉综合征患者冠状动脉疾病复杂性的关联
J Clin Med. 2021 May 20;10(10):2210. doi: 10.3390/jcm10102210.